We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

103 hedge funds and large institutions have $388M invested in BioXcel Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 25

3% more capital invested

Capital invested by funds: $378M → $388M (+$9.86M)

0.07% less ownership

Funds ownership: 2.93% → 2.86% (-0.07%)

4% less call options, than puts

Call options by funds: $6.54M | Put options by funds: $6.84M

5% less funds holding

Funds holding: 108 → 103 (-5)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

Holders
103
Holders Change
-5
Holders Change %
-4.63%
% of All Funds
1.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
50
Reduced
25
Closed
17
Calls
$6.54M
Puts
$6.84M
Net Calls
-$301K
Net Calls Change
+$2.7M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.4M
2
AIM
Artemis Investment Management
United Kingdom
+$5.14M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$3.57M
4
BlackRock
BlackRock
New York
+$2.32M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$2.12M

Top Sellers

Rank Fund Capital Flow
1
AS
Altshuler Shaham
Israel
-$6.86M
2
CCM
CAAS Capital Management
New York
-$6.75M
3
GCM
Ghisallo Capital Management
Massachusetts
-$5.63M
4
LM
Luminus Management
Texas
-$4.57M
5
Blackstone Inc
Blackstone Inc
New York
-$4.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
101
Anchor Investment Management
South Carolina
$1.03K +$879 +2 New
BCA
102
Berman Capital Advisors
Georgia
$1K +$879 +2 New
S
103
SignatureFD
Georgia
$1K +$1.32K +3 New
CCM
104
CAAS Capital Management
New York
– -$6.75M -14,518 Closed
LM
105
Luminus Management
Texas
– -$4.57M -9,819 Closed
Blackstone Inc
106
Blackstone Inc
New York
– -$4.36M -9,375 Closed
LCM
107
Laurion Capital Management
New York
– -$2.91M -6,250 Closed
MIM
108
Monashee Investment Management
Massachusetts
– -$1.74M -3,750 Closed
HF
109
HRT Financial
New York
– -$1.54M -3,321 Closed
KCM
110
Kennedy Capital Management
Missouri
– -$1.18M -2,533 Closed
GH
111
GAM Holding
Switzerland
– -$453K -975 Closed
HAG
112
HighPoint Advisor Group
Illinois
– -$354K -762 Closed
TC
113
TwinBeech Capital
New York
– -$254K -547 Closed
EGM
114
Engineers Gate Manager
New York
– -$222K -478 Closed
BFM
115
Boothbay Fund Management
New York
– -$209K -449 Closed
Russell Investments Group
116
Russell Investments Group
United Kingdom
– -$18K -40 Closed
ASN
117
Advisory Services Network
Georgia
– -$9K -20 Closed
GAM
118
Gemmer Asset Management
California
– -$3K -6 Closed
TWA
119
TCI Wealth Advisors
Arizona
– -$2K -4 Closed
Northwestern Mutual Wealth Management
120
Northwestern Mutual Wealth Management
Wisconsin
– -$1K -2 Closed
1 2 3 4
5

BTAI Hedge Fund Activity: Q3 2021 in Review

103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2021, worth a combined $388M — up 2.6% from $378M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BTAI and 12 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 50 added.

The largest buyer was Fidelity Investments, adding an estimated $18.4M. The largest seller was Altshuler Shaham, cutting an estimated $6.86M.

  • 103 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2021, down from 108 in Q2 2021.
  • Funds reported $388M of BioXcel Therapeutics stock for Q3 2021, up 2.6% quarter-over-quarter.
  • 12 funds opened new BioXcel Therapeutics positions in Q3 2021 and 17 closed out, a net change of -5 holders.
  • The largest BioXcel Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $18.4M added.
  • The largest BioXcel Therapeutics seller in Q3 2021 was Altshuler Shaham, an estimated $6.86M sold.

Based on aggregated 13F filings for Q3 2021.